EGFR delE709_T710insD: a rare but potentially EGFR inhibitor responsive mutation in non-small-cell lung cancer.
作者信息
Ackerman Allison, Goldstein Michael A, Kobayashi Susumu, Costa Daniel B
机构信息
Department of Medicine, Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
出版信息
J Thorac Oncol. 2012 Oct;7(10):e19-20. doi: 10.1097/JTO.0b013e3182635ab4.
Abstract
摘要
相似文献
1
EGFR delE709_T710insD: a rare but potentially EGFR inhibitor responsive mutation in non-small-cell lung cancer.表皮生长因子受体（EGFR）E709_T710缺失并插入D：非小细胞肺癌中一种罕见但可能对EGFR抑制剂敏感的突变
J Thorac Oncol. 2012 Oct;7(10):e19-20. doi: 10.1097/JTO.0b013e3182635ab4.
2
Erlotinib response in an NSCLC patient with a novel compound G719D+L861R mutation in EGFR.一名非小细胞肺癌患者携带表皮生长因子受体（EGFR）新型复合突变G719D+L861R对厄洛替尼的反应
J Thorac Oncol. 2013 Sep;8(9):e83-4. doi: 10.1097/JTO.0b013e31829ceb8d.
3
Personalized medicine and inhibition of EGFR signaling in lung cancer.肺癌中的个性化医疗与表皮生长因子受体信号传导抑制
N Engl J Med. 2009 Sep 3;361(10):1018-20. doi: 10.1056/NEJMe0905763. Epub 2009 Aug 19.
4
Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations.表皮生长因子受体（EGFR）突变的肺癌对吉非替尼获得性耐药并携带L747S或T790M继发性突变时，对厄洛替尼的不同反应。
J Clin Oncol. 2008 Mar 1;26(7):1182-4; author reply 1184-6. doi: 10.1200/JCO.2007.14.9039.
5
EGFR exon 18 delE709_T710insD mutated stage IV lung adenocarcinoma with response to afatinib.表皮生长因子受体（EGFR）第18外显子E709_T710缺失并插入D突变的IV期肺腺癌，对阿法替尼有反应。
Lung Cancer. 2017 Jun;108:45-47. doi: 10.1016/j.lungcan.2017.02.023. Epub 2017 Mar 1.
6
Efficacy of afatinib treatment for lung adenocarcinoma harboring exon 18 delE709_T710insD mutation.阿法替尼治疗携带外显子 18 delE709_T710insD 突变的肺腺癌的疗效。
Jpn J Clin Oncol. 2019 Aug 1;49(8):786-788. doi: 10.1093/jjco/hyz086.
7
Time for molecularly targeted maintenance therapy for non-small-cell lung cancer?非小细胞肺癌分子靶向维持治疗的时机到了吗？
Lancet Oncol. 2010 Jun;11(6):500-1. doi: 10.1016/S1470-2045(10)70120-0. Epub 2010 May 20.
8
Serum concentrations of Erlotinib at a dose of 25 mg daily.每日剂量为25毫克时厄洛替尼的血清浓度。
J Thorac Oncol. 2010 Aug;5(8):1311-2. doi: 10.1097/JTO.0b013e3181edf55c.
9
NICE guidance on erlotinib for first-line treatment of EGFR-TK mutation-positive advanced or metastatic non-small-cell lung cancer.英国国家卫生与临床优化研究所（NICE）关于厄洛替尼用于表皮生长因子受体酪氨酸激酶（EGFR-TK）突变阳性的晚期或转移性非小细胞肺癌一线治疗的指南。
Lancet Oncol. 2012 Aug;13(8):764-5. doi: 10.1016/s1470-2045(12)70296-6.
10
The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations.表皮生长因子受体突变的晚期非小细胞肺癌中初始吉非替尼或厄洛替尼与化疗对中枢神经系统进展的影响。
Clin Cancer Res. 2012 Aug 15;18(16):4406-14. doi: 10.1158/1078-0432.CCR-12-0357. Epub 2012 Jun 25.
引用本文的文献
1
Case Report: Durable therapy response to Osimertinib in rare EGFR Exon 18 mutated NSCLC.病例报告：奥希替尼对罕见的表皮生长因子受体（EGFR）第18外显子突变的非小细胞肺癌（NSCLC）有持久的治疗反应。
Front Oncol. 2023 Aug 16;13:1182391. doi: 10.3389/fonc.2023.1182391. eCollection 2023.
2
exon 20 insertion mutations and mutations in lung cancer: a narrative review on approved targeted therapies from oral kinase inhibitors to antibody-drug conjugates.20号外显子插入突变与肺癌：关于从口服激酶抑制剂到抗体药物偶联物等已获批靶向治疗的叙述性综述
Transl Lung Cancer Res. 2023 Jul 31;12(7):1590-1610. doi: 10.21037/tlcr-23-98. Epub 2023 Jul 5.
3
Response to dacomitinib in advanced non-small-cell lung cancer harboring the rare delE709_T710insD mutation: A case report.携带罕见delE709_T710insD突变的晚期非小细胞肺癌对达可替尼的反应：一例报告
World J Clin Cases. 2022 Jun 16;10(17):5916-5922. doi: 10.12998/wjcc.v10.i17.5916.
4
Afatinib for the treatment of advanced non-small-cell lung cancer harboring an epidermal growth factor receptor exon 18 E709_T710delinsD mutation: a case report.阿法替尼治疗携表皮生长因子受体外显子 18 E709_T710delinsD 突变的晚期非小细胞肺癌：一例报告。
J Med Case Rep. 2021 Nov 22;15(1):562. doi: 10.1186/s13256-021-02994-0.
5
Complete Response to Afatinib of an EGFR Exon 18 delE709_T710insD-Mutated Stage IV Lung Adenocarcinoma.EGFR外显子18 delE709_T710insD突变的IV期肺腺癌对阿法替尼完全缓解
Eur J Case Rep Intern Med. 2021 Aug 11;8(8):002749. doi: 10.12890/2021_002749. eCollection 2021.
6
A Nationwide Study on the Impact of Routine Testing for Mutations in Advanced NSCLC Reveals Distinct Survival Patterns Based on Mutation Subclasses.一项关于晚期非小细胞肺癌（NSCLC）突变常规检测影响的全国性研究揭示了基于突变亚类的不同生存模式。
Cancers (Basel). 2021 Jul 20;13(14):3641. doi: 10.3390/cancers13143641.
7
A Lung Adenocarcinoma Patient With a Rare E709_T710delinsD Mutation Showed a Good Response to Afatinib Treatment: A Case Report and Literature Review.一名患有罕见E709_T710delinsD突变的肺腺癌患者对阿法替尼治疗反应良好：病例报告及文献综述
Front Oncol. 2021 Jun 11;11:700345. doi: 10.3389/fonc.2021.700345. eCollection 2021.
8
Great efficacy of afatinib on a patient with lung adenocarcinoma harboring uncommon EGFR delE709_T710insD mutations: a case report.阿法替尼对一名携带罕见EGFR delE709_T710insD突变的肺腺癌患者具有显著疗效：一例病例报告。
Onco Targets Ther. 2019 Sep 10;12:7399-7404. doi: 10.2147/OTT.S221638. eCollection 2019.
9
Analysis of Predictive Biomarkers in Patients With Lung Adenocarcinoma From Southern Brazil Reveals a Distinct Profile From Other Regions of the Country.巴西南部肺腺癌患者预测生物标志物分析显示与该国其他地区不同的特征。
J Glob Oncol. 2019 Sep;5:1-9. doi: 10.1200/JGO.19.00174.
10
Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario.不同寻常的表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKI）在罕见 EGFR 突变患者中的反应：在这一复杂临床情况下的新见解和未来展望。
Int J Mol Sci. 2019 Mar 21;20(6):1431. doi: 10.3390/ijms20061431.
本文引用的文献
1
Encouragement to submit data of clinical response to EGFR-TKIs in patients with uncommon EGFR mutations.鼓励提交具有罕见表皮生长因子受体（EGFR）突变的患者对EGFR酪氨酸激酶抑制剂（TKIs）临床反应的数据。
J Thorac Oncol. 2012 May;7(5):775-6. doi: 10.1097/JTO.0b013e318251980b.
2
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.厄洛替尼对比标准化疗用于治疗欧洲晚期 EGFR 突变阳性非小细胞肺癌患者的一线治疗（EURTAC）：一项多中心、开放标签、随机、3 期临床试验。
Lancet Oncol. 2012 Mar;13(3):239-46. doi: 10.1016/S1470-2045(11)70393-X. Epub 2012 Jan 26.
3
Genotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalities.针对非小细胞肺癌的基因驱动治疗：聚焦于 EGFR、KRAS 和 ALK 基因异常。
Ther Adv Med Oncol. 2011 May;3(3):113-25. doi: 10.1177/1758834010397569.
4
Including total EGFR staining in scoring improves EGFR mutations detection by mutation-specific antibodies and EGFR TKIs response prediction.在评分中纳入总 EGFR 染色可提高突变特异性抗体检测 EGFR 突变和 EGFR TKIs 反应预测的准确性。
PLoS One. 2011;6(8):e23303. doi: 10.1371/journal.pone.0023303. Epub 2011 Aug 9.
5
EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications.非小细胞肺癌中 EGFR 外显子 20 插入突变：临床前数据及临床意义。
Lancet Oncol. 2012 Jan;13(1):e23-31. doi: 10.1016/S1470-2045(11)70129-2. Epub 2011 Jul 19.
6
Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer.酪氨酸激酶抑制剂对非小细胞肺癌中未知临床意义的“罕见”表皮生长因子受体突变的疗效。
Clin Cancer Res. 2011 Jun 1;17(11):3812-21. doi: 10.1158/1078-0432.CCR-10-3408. Epub 2011 Apr 29.
Zotero 插件